https://www.selleckchem.com/pr....oducts/KU-0063794.ht
05) at all time points. Among 36 right eyes in the MED group, mean medication use was 1.9 (0.9) at baseline and ranged from 1.2 to 1.4 medications per eye through follow-up (p 0.0033), and mean IOP was significantly reduced at months 1-6 (to 13.1 (2.3) mm Hg, p=0.0013), months 13-18 (to 14.3 (2.8), p=0.0136) and unchanged at other time points. No vision-threatening adverse events occurred. Afro-Caribbean patients with OAG at risk for progression can achieve clinically and statistically significant reductions in IOP or medications thr
Like
Comment
Share
